Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study
Ist Teil von
Hepatology research, 1998-12, Vol.13 (1), p.10-19
Ort / Verlag
Shannon: Elsevier Ireland Ltd
Erscheinungsjahr
1998
Beschreibungen/Notizen
Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (
P<0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (
P<0.05). A progressive improvement of alanine aminotransferase (ALT) with time (
P<0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.